A reference library for modern health, structured the way clinicians actually think — by biomarker, by compound, by mechanism, by population. Every claim cited1. Every page reviewed.
A starter reference. Optimal ranges based on the evidence we cite, not standard lab cutoffs — those are population averages, not health goals.2
| Marker | Standard range | Optimal range | Why it matters | Evidence |
|---|---|---|---|---|
| ApoB | < 100 mg/dL | < 70 mg/dL | Best single predictor of ASCVD risk | Strong |
| hs-CRP | < 3.0 mg/L | < 1.0 mg/L | Systemic inflammation; CV + metabolic | Strong |
| Fasting insulin | 2–25 µIU/mL | < 8 µIU/mL | Insulin resistance, decades before glucose | Strong |
| Ferritin | 12–300 ng/mL | 50–150 ng/mL | Iron stores; energy + cognition | Moderate |
| Estradiol (premenop) | 15–350 pg/mL | cycle-dependent | Bone, brain, vascular; not optional | Strong |
| Free T3 | 2.3–4.2 pg/mL | 3.2–4.0 pg/mL | The active thyroid hormone | Moderate |
| HbA1c | < 5.7% | < 5.4% | 3-mo glucose; metabolic trajectory | Strong |
A decade after the WHI re-analyses, the science has moved. Yet most women are still being prescribed — or denied — hormone therapy based on a study from 2002. We mapped the modern evidence, the timing hypothesis, and what to actually ask for.
One issue a week. A featured long read, this week's reference cards, and the new evidence worth knowing. Sent Sunday.
Free · 211,408 readers · No tracking